Clinical trial • Phase I • Cardiology

VERVE-201 for Refractory hyperlipidemia

Phase I trial of VERVE-201 for Refractory hyperlipidemia. 92 participants.

Overview

Trial Therapeutic Area
Cardiology
Trial Disease
Refractory hyperlipidemia
Trial Stage
Phase I

Key dates

Initial CTIS Submission Date
25-11-2025
First CTIS Authorization Date
30-03-2026

Trial design

Phase I trial across 2 sites in Netherlands.

Target Sample Size
92

Eligibility

Recruits 92 No vulnerable population selected; consent or assent handling not described in available documentation..

Vulnerable Population
No vulnerable population selected; consent or assent handling not described in available documentation.

Recruitment

Planned Sample Size
92
Recruitment Window Months
16
Consent Approach
Informed consent and assent process not described in the available CTIS record.

Geography

Total Number Of Sites
2
Total Number Of Participants
92

Netherlands

Earliest CTIS Part Ii Submission Date
25-03-2026
Latest Decision Or Authorization Date
30-03-2026
Processing Time Days
5
Number Of Sites
2
Number Of Participants
10

Sites

Site Name
Academisch Medisch Centrum
Department Name
Vascular Medicine
Principal Investigator Name
Erik Stroes
Principal Investigator Email
e.s.stroes@amsterdamumc.nl
Contact Person Name
Erik Stroes
Contact Person Email
e.s.stroes@amsterdamumc.nl
Site Name
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Department Name
Internal Medicine
Principal Investigator Name
Jeanine Roeters van Lennep
Principal Investigator Email
j.roetervanlennep@erasmusmc.nl
Contact Person Name
Jeanine Roeters van Lennep
Contact Person Email
j.roetervanlennep@erasmusmc.nl

Sponsor

Primary sponsor

Full Name
Verve Therapeutics Inc.
Organisation Type
Pharmaceutical company
Country Of Registered Address
United States

Investigational products

Investigational Product Name
VERVE-201

Related trials

Other published trials that may interest you.